Community Infections

Vulvovaginal candidiasis

Common and disruptive, yet often ignored or minimized.

Vulvovaginal candidiasis (VVC), commonly known as a vaginal yeast infection due to Candida, is the second most common vaginal infection affecting women of reproductive age in the United States. An estimated 75% of women worldwide will have at least one episode of VVC in their lifetime, and 40-50% of those will experience multiple episodes.

Although frequently caused by Candida albicans, infections caused by fluconazole-resistant and non-albicans Candida strains, such as Candida glabrata, have been reported to be on the rise.

Itching. Burning. Pain.

VVC can be associated with significant discomfort (pain, itching, burning), reduced sexual pleasure and activity, psychological distress (stress, depression, anxiety), embarrassment, reduced physical activity, and loss of productivity.

Though common, vaginal yeast infections are sometimes dismissed or ignored as not serious. VVC can be a debilitating condition associated with an estimated 1.4 million outpatient visits each year.

Fungi are evolving organisms that have increasingly become resistant to treatment with azoles.

  • 75%

    of women in the United States experience at least one acute vaginal yeast infection in their lifetime1.

Reference: 1.Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339-e347.

The symptoms of vaginal candidiasis include:

  • Hand
    Vaginal itching or soreness
  • Bolt
    Pain or discomfort when urinating
  • Bolt
    Pain during sexual intercourse
  • Drops
    Abnormal vaginal discharge

Risk factors

  • Genetic predisposition
  • Use of systemic or vaginal antibiotics
  • Use of high-dose, estrogen-containing contraceptives
  • Intrauterine device
  • Hormone replacement therapy
  • Sexual activity
  • Diabetes mellitus
  • Immunocompromising conditions
  • Use of diabetic medications

Clinical Trials

Vanish 303 & 306

Ibrexafungerp for Vulvovaginal Candidiasis (VVC)

Additional trial information


Phase 3b, open-label, multicenter study to evaluate the efficacy, safety and tolerability of oral ibrexafungerp as a treatment for complicated vulvovaginal candidiasis (VVC) in patients who have failed treatment with fluconazole, based on mycological and clinical outcomes.

Additional trial information

Our data on invasive infections

SCYNEXIS regularly presents key infectious disease study data at top medical meetings.

Learn More

Our pipeline

SCYNEXIS has ongoing research in community infections.

Learn More